Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice

被引:5
|
作者
Bonet, Marta [1 ]
Garcia, Virginia [1 ]
Farre, Nuria [2 ]
Algara, Manel [3 ]
Farrus, Blanca [4 ]
Fernandez, Jaume [5 ]
Reyes, Victoria [6 ]
Eraso, Arancha [7 ]
Alvarez, Ana [8 ]
Jose Cambra, Maria [9 ]
Pedro, Agusti [10 ]
Vayreda, Jordi [11 ]
Lemansky, Claire [12 ]
Izar, Francoise [13 ]
Arenas, Meritxell [14 ]
机构
[1] Hosp Arnau Vilanova, Dept Radiat Oncol, Av Alcalde Rovira Roure 80, Lleida 25198, Spain
[2] Hosp Santa Creu & Sant Pau, Dept Radiat Oncol, Barcelona, Spain
[3] Parc Salut Mar, Dept Radiat Oncol, Barcelona, Spain
[4] Hosp Clin Barcelona, Dept Radiat Oncol, Barcelona, Spain
[5] Hosp Quiron, Dept Radiat Oncol, Barcelona, Spain
[6] Hosp Valle De Hebron, Dept Radiat Oncol, Barcelona, Spain
[7] Hosp Duran & Reynals, Dept Radiat Oncol, Inst Catala Oncol, Barcelona, Spain
[8] Hosp Badalona Germans Trias & Pujol, Dept Radiat Oncol, Inst Catala Oncol, Badalona, Spain
[9] Hosp Gen Cataluna, Inst Oncol Valles, Sant Cugat Del Valles, Spain
[10] Hosp Plato, Dept Radiat Oncol, Barcelona, Spain
[11] Hosp Josep Trueta, Dept Radiat Oncol, Inst Catala Oncol, Girona, Spain
[12] Univ Montpellier, Inst Cancerol Montpellier Val dAurelle, Dept Radiat Oncol, Montpellier, France
[13] Inst Univ Canc Toulouse, Dept Radiat Oncol, Toulouse, France
[14] Hosp Univ St Joan de Reus, Dept Radiat Oncol, Tarragona, Spain
关键词
Bone metastases; Oligometastases; Breast cancer; Radiation therapy; SBRT; STEREOTACTIC BODY RADIOTHERAPY; PROGNOSIS; ACHIEVE;
D O I
10.1016/j.rpor.2019.12.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The role of radiation therapy (RT) for patients with bone-only metastatic (BOM) breast cancer has not been investigated sufficiently. The aim of this survey was to evaluate current clinical practice in treating breast cancer patients with BOM in Radiation Therapy Departments in Catalonia and Occitania within the scope of the GOCO group. Materials and methods: An electronic questionnaire was completed by experienced radiation oncologists from fourteen RT centers. The items surveyed the professional experience, therapeutic approach, technique, dose stereotactic body RT (SBRT) availability. Results: All Radiation Oncology Departments (ROD) in Catalonia (12) and Occitania (2) responded to the survey. Eleven (78.5%) of the RODs advise RT for BOM as initial treatment in the oligometastatic setting. RT to asymptomatic bone oligometastases is more often restricted for "risky lesions". The most inconsistent approaches were the treatment for asymptomatic lesions, when to treat bone metastases with respect to systemic treatment (ST) and the indication for RT after a complete response to ST. Conclusion: While BOM breast cancer patients have a relatively good prognosis, there is a lack of consistency in their approach with RT. This can be explained by the absence of evidence-based guidelines and an incomplete availability of SBRT. (C) 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:113 / 116
页数:4
相关论文
共 50 条
  • [1] RT for bone-only oligometastases in breast cancer patients: a survey of current clinical practice.
    Bonet, M.
    Arenas, M.
    Farre, N.
    Garcia, V.
    Algara, M.
    Farrus, B.
    Fernandez, J.
    Reyes, V.
    Eraso, A.
    Alvarez, A.
    Cambra, M.
    Pedro, A.
    Vayreda, J.
    Montero, A.
    Poortmans, P.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S711 - S712
  • [2] Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases
    Parkes, Amanda
    Warneke, Carla L.
    Clifton, Katherine
    Al-Awadhi, Aydah
    Oke, Oluchi
    Pestana, Roberto Carmagnani
    Alhalabi, Omar
    Litton, Jennifer K.
    Hortobagyi, Gabriel N.
    ONCOLOGIST, 2018, 23 (11): : 1282 - 1288
  • [3] Survival After Palliative Radiotherapy in Patients with Breast Cancer and Bone-only Metastases
    Nieder, Carsten
    Dalhaug, Astrid
    Pawinski, Adam
    Mannsaker, Bard
    Haukland, Ellinor
    IN VIVO, 2016, 30 (06): : 879 - 883
  • [4] Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer
    Curtit, E.
    Bazan, F.
    Chaigneau, L.
    Mouillet, G.
    Dobi, E.
    Mansi, L.
    Meneveau, N.
    Paillard, M-J.
    Meynard, G.
    Klajer, E.
    Villanueva, C.
    Montcuquet, P.
    Pivot, X.
    Cals, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Pilot Study of Targeted Skeletal Radiation Therapy for Bone-Only Metastatic Breast Cancer
    Ueno, Naoto T.
    de Souza, Jonas A.
    Booser, Daniel
    Nakayama, Kazutaka
    Madewell, John
    Wendt, Richard E., III
    Hortobagyi, Gabriel N.
    Podoloff, Donald
    Charnplin, Richard E.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 173 - 177
  • [6] ADVANCED BREAST-CANCER WITH BONE-ONLY METASTASES - A CHEMOTHERAPEUTICALLY RESPONSIVE PATTERN OF METASTASES
    SMALLEY, RV
    SCOGNA, DM
    MALMUD, LS
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (02): : 161 - 166
  • [7] Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases
    Niikura, Naoki
    Liu, Jun
    Hayashi, Naoki
    Palla, Shana L.
    Tokuda, Yutaka
    Hortobagyi, Gabriel N.
    Ueno, Naoto T.
    Theriault, Richard L.
    CANCER, 2012, 118 (08) : 2039 - 2047
  • [8] Prognostic Factors for Patients with Bone-Only Metastasis in Breast Cancer
    Ahn, Sung Gwe
    Lee, Hak Min
    Cho, Sang-Hoon
    Lee, Seung Ah
    Hwang, Seung Hyun
    Jeong, Joon
    Lee, Hy-De
    YONSEI MEDICAL JOURNAL, 2013, 54 (05) : 1168 - 1177
  • [9] BREAST-CANCER WITH BONE-ONLY METASTASES - VISCERAL METASTASES-FREE RATE IN RELATION TO ANATOMIC DISTRIBUTION OF BONE METASTASES
    YAMASHITA, K
    UEDA, T
    KOMATSUBARA, Y
    KOYAMA, H
    INAJI, H
    YONENOBU, K
    ONO, K
    CANCER, 1991, 68 (03) : 634 - 637
  • [10] Clinical Value of Surgery and Establishment a Predictive Model for Breast Cancer Patients with Bone-Only Metastasis
    Wang, Zongpan
    Wu, Rongxing
    Qiu, Dan
    Zhou, Shaofang
    DISCOVERY MEDICINE, 2023, 35 (174) : 73 - 81